Guidance missed: domestic flat, emerging −31%, margins compressed

International +2.8% YoY; emerging −31%; Europe flat 2.5%; US +62% but small base

Domestic formulations INR2,040 Cr vs INR2,028 Cr YoY; essentially flat

Standalone EBITDA margin 10.3% vs 14.7% QoQ; gross margin hit 200 bps YoY

API revenue INR521 Cr, +42.4% YoY; confirmed

Management cited order book but shipping delays in Europe Q1, secondary demand uncertain

Prior call expected continued momentum; Q1 emerged −31% YoY (INR317 vs INR461 Cr). Management now frames as 'temporary' but secondary demand not corroborating.

Expected recovery in line with IPM; delivered INR2,040 Cr flat vs INR2,028 Cr YoY. Anti-infectives and respiratory seasonal miss, but core franchise not reaccelerating.

EBITDA margin 10.3% vs 14.7% QoQ, despite 'efficiency' narrative. COGS hit 200 bps; partly persists Q3. Operating leverage not yet visible.

Management stopped guiding on FDA audit timing; 'keeping fingers crossed.' Prior implication of near-term approval now deferred to 'soon, but unclear when.'

Emerging was March quarter push + war-induced shortages, temporary. April-March combined better. Europe timing issue, no fundamentals wrong. Order book strong.

Better to not say too much about ophthalmics. Wait for USFDA audit, then discuss concretely.

India and emerging highly profitable. Europe scale will add profit. U.S. still in growth mode, WC challenged. Expect profit when these scale.

Working capital (short-term) varies ₹300–330 Cr; FX losses on euro loan included. Pure interest ~₹20 Cr/quarter.

Post-COVID normalization; new product launches (₹100 Cr MAT). Brand building required for India and Warren.

Partly impact into Q3, then normalizes. No explicit pricing actions mentioned.

INR34 Cr revenue, marginal loss (EBITDA INR6 Cr overall for Warren). Needs 3 years consistent advertising support.

6+ months waiting, assurances received but not materialized. Stop guessing; fingers crossed. Not endless wait, but patience running out.

Maintenance capex only, max ₹40–50 Cr total. Tax: regular bracket; carryforward losses, effective rate much lower.

Yes, directly in line. Includes new products. Capacity at 70–80% utilization, room to expand.

Domestic currently flat; emerging −31%. Guidance conditional on midsized brands scaling and seasonal recovery. Vague on timing.

Management reaffirmed 'on track' but Europe flat, US +62% on small base. Order book ₹250 Cr cited but shipping delays in Q1. Execution uncertain.

Vague timeline ('few years'). Contingent on API ramp, US FDA clarity, and domestic recovery. No formal guidance, just MD aspirational statement.

Q1 EBITDA 8.8% consolidated, down from 10.9% QoQ. Management frames as temporary (COGS, Warren losses) but no numeric target. Vague.

No formal guidance, but MD's aspiration. Requires ₹250+ Cr EBITDA on ₹2,400+ Cr revenue. Feasible if domestic + international reaccelerate and Warren breaks even.

Confirmed multiple times; major capex (Warren API, Baddi expansions) already spent. No new facility buildouts planned.

US sterile formulations plant unable to supply; USFDA audit pending since 6+ months. MD conceded U.S. sterile 'not profitable yet.' Remediation costs high. Delays block INR459+ Cr US opportunity.

Emerging market revenue INR317 Cr vs INR461 Cr YoY, −31% decline. Management blamed March quarter push and war-induced shortages, claiming secondary demand 'extremely steady.' But primary decline is material and contradicts prior bullish stance.

Domestic revenue INR2,040 Cr vs INR2,028 Cr YoY, essentially flat. Management cited anti-infectives and respiratory seasonal miss (no June rains). But if top 10 brands are in 'double-digit growth,' stagnation signals portfolio hollowing or market share loss outside flagship brands.

EBITDA margin 8.8% consolidated vs 10.9% QoQ; 200 bps COGS hit from war. Warren Remedies marginal loss (EBITDA INR6 Cr on INR34 Cr OTC revenue). Operating leverage from 26% fewer batches and 900 headcount reduction not yet visible.

Debt INR930 Cr; interest cost INR28 Cr/quarter (~3% of revenue) includes FX MTM losses on euro loan and working capital financing. Analyst questioned reconciliation; CFO's answer was opaque. High variability of short-term debt (₹300–330 Cr range) complicates planning.

Warren Remedies OTC oral care business INR34 Cr revenue, marginal loss (INR6 Cr EBITDA overall). Requires 'at least 3 years very consistent support' in advertising/digital marketing to compete with Sensodyne incumbency. API platform at Warren also early-stage (awaiting USFDA approval).